Chemokines and Motor Symptoms in First-Episode Psychosis: Are We Overlooking One of the Puzzle Pieces in Understanding the Neurological Immune Mechanisms behind Them?
Elevated levels of potential neurotoxic (CCL2) and neuroprotective (PPARα and CB2) biomarkers were seen in FEP patients when compared to controls. Moreover, CCL2 levels seem to be directly associated with Parkinsonism in FEP patients, while CXCR4 may be protective against extrapyramidal symptoms. Further research should clarify immune differences between FEP and non-FEP groups, especially in chemotaxis and endocannabinoid pathways.
Authors
- María Flores-López (ORCID: https://orcid.org/0000-0003-3489-1465)
- Ana M. Sánchez-Torres (ORCID: https://orcid.org/0000-0002-9505-2406)
- Ana Gavito (ORCID: https://orcid.org/0000-0002-2782-5999)
- Manuel J Cuesta
- Fernándo Rodríguez de Fonseca
- Antonia Serrano
- Alejandro Ballesteros
- Eloi Giné-Servén
Institutions
- Universidad Pública de Navarra (UPNA) (ES)
- Hospital Regional Universitario de Málaga (ES)
- Navarre Institute of Health Research (ES)
- Andalusian Centre for Nanomedicine and Biotechnology (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
Publication Details
- Journal
- Neuropsychobiology
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1159/000549183
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00